Company Profile
StemCyte International, Ltd., a biotechnology company develops cord bloodยbased cell therapies in the United States and Taiwan. The company engages in the R&D of biotechnology and cell-based new drugs.
Its portfolio also includes supply of cellular materials, and operation of cord blood cell banks, as well as umbilical cord blood transplantation services; and cell products and services.
Additionally, it provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders for post-covid, acute stroke, and cerebral palsy.
It also develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies. Founded in 1997, the company is based in Taipei, Taiwan. StemCyte International, Ltd. operates as a subsidiary of Diamond Biofund Inc.